Clinical trial · Observational
Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030
The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples
NCT00899535CI-TRIAL-00022770completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA analysis | Genetic | — | UNRESOLVED |
| microarray analysis | Genetic | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
| RNA analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- interventionNames
- Genetic: DNA analysis
- Genetic: RNA analysis
- Genetic: microarray analysis
- Genetic: mutation analysis
- Genetic: polymorphism analysis
Primary outcomes (1)
- measure
- Clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens
- timeFrame
- Up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of non-small cell carcinoma
* Primary, untreated disease
* Stage I or II (T1 or T2, N0 or non-hilar N1, M0) disease
* Any of the following histologies allowed:
* Squamous cell carcinoma
* Adenocarcinoma (\< 10%)
* Large cell carcinoma (high-grade)
* Available tumor tissue samples collected on clinical trial ACOSOG-Z0030 and meeting the following criteria:
* Snap-frozen and stored at a temperature of -80°C or lower
* Specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung
* No regional lymph node or distant metastases
* No recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer
* Must have matching frozen samples of normal tissue and bloodReferences
Publications (0)
Data not yet available
No reference posted for this study.